Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses

Liu, Xiang; Feng, Zujian; Wang, Changrong; Su, Qi; Song, Huijuan; Zhang, Chuangnian; Huang, Pingsheng; Liang, Xing‐Jie; Dong, Anjie; Kong, Deling; Wang, Weiwei

doi:10.1016/j.biomaterials.2019.119649

Cited by 110 publications

(65 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, release of immunostimulatory agents from nanovaccine in tumor sites assists in the stimulation of DCs, causing a significant improvement in tumor-specific CD8 + T-cell response. This combination induces a strong tumor-specific CD8 + T-cell responses that significantly inhibit tumor growth [86]. Together, these studies suggest that combining immunotherapy with chemotherapy via nanomedicines offers a strategy for better treatment of breast cancer.…”

Section: Combination With Chemotherapymentioning

confidence: 88%

“…Moreover, co-application of doxorubicin-loaded micelles with imiquimod-loaded micelles was observed to trigger strong CTL responses towards 4T1 orthotopic tumor in mice and significantly diminish tumor growth and metastasis [85]. Liu et al [86] designed a nanomedicine consisting of curcumin (a natural antitumor compound found in the spice turmeric)-loaded polymeric nanoparticles and a nanovaccine containing CpG and antigenic peptides. After injection in 4T1 breast cancer model, this nanomedicine efficiently triggers immunogenic cell death (ICD) of cancer cells and activation of DCs.…”

Section: Combination With Chemotherapymentioning

confidence: 99%

See 1 more Smart Citation

Emerging nanomedicines for effective breast cancer immunotherapy

2020

View full text Add to dashboard Cite

Breast cancer continues to be the most frequently diagnosed malignancy among women, putting their life in jeopardy. Cancer immunotherapy is a novel approach with the ability to boost the host immune system to recognize and eradicate cancer cells with high selectivity. As a promising treatment, immunotherapy can not only eliminate the primary tumors, but also be proven to be effective in impeding metastasis and recurrence. However, the clinical application of cancer immunotherapy has faced some limitations including generating weak immune responses due to inadequate delivery of immunostimulants to the immune cells as well as uncontrolled modulation of immune system, which can give rise to autoimmunity and nonspecific inflammation. Growing evidence has suggested that nanotechnology may meet the needs of current cancer immunotherapy. Advanced biomaterials such as nanoparticles afford a unique opportunity to maximize the efficiency of immunotherapy and significantly diminish their toxic side-effects. Here we discuss recent advancements that have been made in nanoparticle-involving breast cancer immunotherapy, varying from direct activation of immune systems through the delivery of tumor antigens and adjuvants to immune cells to altering immunosuppression of tumor environment and combination with other conventional therapies.

show abstract

Section: Combination With Chemotherapymentioning

confidence: 88%

Section: Combination With Chemotherapymentioning

confidence: 99%

Emerging nanomedicines for effective breast cancer immunotherapy

2020

View full text Add to dashboard Cite

show abstract

“…Moreover, in patients with metastatic triple-negative breast cancer, the co-administration of nab-paclitaxel plus PD-L1 blockade (atezolizumab) prolonged progression-free survival [ 94 ]. Owing to the success in previous research [ 95 ], clinical trials on nano-immunotherapy are currently underway, such as NCT03589339 , and NCT03684785 . These clinical trials should provide substantial evidence for the combination of nanomedicine and PD-1/PD-L1 blockade in the next few years.…”

Section: Future Perspectivesmentioning

confidence: 99%

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

et al. 2020

View full text Add to dashboard Cite

PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a broad range of malignancies and achieved clinical success. Despite the potentially cure-like survival benefit, only a minority of patients are estimated to experience a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might eventually lead to cancer progression in patients with clinical responses. Accordingly, the resistance to PD-1/PD-L1 blockade remains a significant challenge hindering its further application. To overcome the limitation in therapy resistance, substantial effort has been made to improve or develop novel anti-PD-1/PD-L1 based immunotherapy strategies with better clinical response and reduced immune-mediated toxicity. In this review, we provide an overview on the resistance to PD-1/PD-L1 blockade and briefly introduce the mechanisms underlying therapy resistance. Moreover, we summarize potential predictive factors for the resistance to PD-1/PD-L1 blockade. Furthermore, we give an insight into the possible solutions to improve efficacy and clinical response. In the following research, combined efforts of basic researchers and clinicians are required to address the limitation of therapy resistance.

show abstract

“…One in two patients with metastatic melanoma still require alternative therapies [23]. Several mechanisms involved in the development of resistance to immunotherapy have been described, among them the low tumoral immunogenicity, limited T cell immune response, and others [26].…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Nanosystems for Improved Targeted Therapies in Melanoma

Beiu

Giurcăneanu

Grumezescu

et al. 2020

JCM

View full text Add to dashboard Cite

Melanoma is one of the most aggressive forms of skin cancer, with limited therapeutic options. Since its incidence has been rapidly rising in recent years, the study of new targeted therapeutic strategies has increased. The implication of nanoscience in the development of alternative targeted therapies for melanoma has multiple benefits and could significantly improve the outcome of melanoma patients. In this paper, we review the most recent progress in the field of targeted therapies, emphasizing the impact of nanoscale materials on the targeting and controlled release of anti-tumor drugs. The applications of nanomedicine in the management of melanoma are extensive and refer to sentinel lymph node mapping, chemotherapy, and RNA interference; each of these applications harboring the potential to develop efficient and personalized diagnostic techniques and therapies. Further research, especially in clinical trials, is needed to establish whether fighting melanoma on the nanoscale level represents the key to reaching a critical inflection point in mankind’s battle with metastatic melanoma.

show abstract

Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses

Cited by 110 publications

References 52 publications

Emerging nanomedicines for effective breast cancer immunotherapy

Emerging nanomedicines for effective breast cancer immunotherapy

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Nanosystems for Improved Targeted Therapies in Melanoma

Contact Info

Product

Resources

About